Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer Journal Article
| Authors: | Solomon, B. J.; Zhou, C. C.; Drilon, A.; Park, K.; Wolf, J.; Elamin, Y.; Davis, H. M.; Soldatenkova, V.; Sashegyi, A.; Lin, A. B.; Lin, B. K.; Loong, H. H. F.; Novello, S.; Arriola, E.; Pérol, M.; Goto, K.; Santini, F. C. |
| Article Title: | Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer |
| Abstract: | Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival. © 2021 Benjamin Solomon. |
| Keywords: | targeted therapy; non-small-cell lung cancer; phase iii trial; ret rearrangement; selpercatinib; ret fusion-positive; ret kinase inhibitor |
| Journal Title: | Future Oncology |
| Volume: | 17 |
| Issue: | 7 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2021-03-01 |
| Start Page: | 763 |
| End Page: | 773 |
| Language: | English |
| DOI: | 10.2217/fon-2020-0935 |
| PUBMED: | 33150799 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 March 2021 -- Source: Scopus |
